Acrivon Therapeutics, Inc.

Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Their method is widely applicable across drug classes and modalities. We specifically apply their approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene…More driver mutations or synthetic lethal contexts. Leveraging their unique patient selection platform, Acrivon Therapeutics aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. Acrivon Therapeutics and its clinical biomarker development group is headquartered in the greater Boston area, with biomarker discovery efforts concentrated in their wholly-owned subsidiary in Lund, Sweden.